Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02659514 · ClinicalTrials.gov registry record · Phase 2
Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer
A Phase 2 study, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT02659514 is a Phase 2 study that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 67 participants.
The verdict
NCT02659514, a Phase 2 study, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the dose regimen and evaluate the preliminary efficacy and the safety/tolerability of poziotinib in participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have received at least two prior HER2-directed treatment regimens.
Interventions
- DRUG Poziotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2016-02-22 |
| Est. Completion | 2020-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02659514
The ClinicalTrials.gov registry entry for NCT02659514 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Poziotinib is the first listed.
NCT02659514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02659514 about?
NCT02659514 is a clinical study titled "Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer". The purpose of this study is to establish the dose regimen and evaluate the preliminary efficacy and the safety/tolerability of poziotinib in participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have received at least two prior HER2-directed treatme...
What is the current status of trial NCT02659514?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2016-02-22. Estimated completion is 2020-03-11.
What interventions are being tested in trial NCT02659514?
The interventions under investigation include: Poziotinib (DRUG).
Who is sponsoring clinical trial NCT02659514?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.